Incanthera PLC (INC:LSE) delivered a strong investor update at its 2025 Annual General Meeting, highlighting continued momentum in dermatology innovation and commercial performance following the August 2025 launch of its Skin + Cell skincare range. All AGM resolutions were approved, including auditor reappointment and board re-elections, reinforcing shareholder confidence in the company’s growth strategy. Management reported robust sales trends, high customer retention, and accelerating repeat purchase rates, supported by positive consumer testimonials and growing traction across international markets, particularly Asia. The Skin + Cell brand has demonstrated early profitability within the direct-to-consumer (DTC) model, leveraging targeted digital marketing and data-driven engagement to enhance margins and brand visibility. Strategic priorities include expanding distribution into retail and wholesale channels, launching new product variants such as an SPF aerosol, and developing non-dilutive funding options to sustain growth without equity dilution. Management reaffirmed operational efficiency through its lean “virtual company” structure, which minimizes overhead while maximizing scalability. With strong early adoption, disciplined licensing plans, and a well-defined commercialization roadmap, Incanthera is positioning itself for sustained revenue growth and shareholder value creation in 2026 and beyond.